Why the study?
Do RAAS inhibitors provide neuroprotection and prevent stroke in experimental models and clinical settings?
Do RAAS inhibitors provide neuroprotection and prevent stroke in experimental models and clinical settings?
RAAS inhibitors demonstrate neuroprotective effects in experimental models and show potential for primary and secondary stroke prevention in clinical trials.
May support stroke prevention in high-risk patients; extends experimental data but leaves clinical adoption open.
The renin angiotensin aldosterone system (RAAS) has been implicated in the pathogenesis of cerebrovascular diseases. During the past decades, AU: INCLUDE A NUMBER? RAAS has gained attention as an important therapeutic target in cardiovascular medicine. Modulation of the RAAS for primary and secondary stroke prevention seems an appealing strategy. Several experimental studies have showed that pre-treatment with RAAS inhibitors prior to the initiation of ischemia exerts favorable effects on infarct volume, brain edema, and cerebral blood flow in the marginal zone. Furthermore, the activation of angiotensin receptor type 2 has been associated with neuroprotective effects. Accumulating evidence based on recent clinical trials indicate that blockade of RAAS has a potential role in stroke prevention. This review summarizes the pathophysiological aspects of brain RAAS and its constituents, presents experimental data on the neuroprotective actions of RAAS inhibitors and available evidence regarding their effects on stroke risk, and discuss future directions for research.
No takes yet. Share an insight, caveat, or question.
Moutzouri et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: